You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
The goal is to generate clinical outcome and economic data that will make the case to payors to cover NIPT for average-risk pregnancies.
Illumina plans to develop clinical-grade products and expects that reimbursement and regulatory trends will further drive growth of its technology in the clinic.
A jury agreed that Ariosa's noninvasive prenatal test infringed several claims in two patents held by Illumina.
Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.
Premaitha entered into a secured loan facility agreement with Thermo Fisher, which is secured on the shares of Premaitha's Taiwanese subsidiary, Yourgene Bioscience.
Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.
The Chinese government has implemented clearer regulatory guidance for genomic tests and invested in both clinical testing and research, spurring growth.
The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.
The companies will work together on a new sequencing-based NIPT technology developed by 10x Genomics for the Chinese market.